(NASDAQ: SLDB) Solid Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Solid Biosciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast SLDB's revenue for 2027 to be $4,607,901,586, with the lowest SLDB revenue forecast at $3,519,198,116, and the highest SLDB revenue forecast at $5,696,605,056. On average, 4 Wall Street analysts forecast SLDB's revenue for 2028 to be $9,315,798,008, with the lowest SLDB revenue forecast at $1,999,121,573, and the highest SLDB revenue forecast at $20,278,022,623.
In 2029, SLDB is forecast to generate $23,613,664,326 in revenue, with the lowest revenue forecast at $13,434,965,142 and the highest revenue forecast at $29,223,297,129.